Hospital
Eisenhower Medical Center
Eisenhower Medical Center was paid $97.77M by Medicaid between Jan 2018 and Nov 2024, across 468 billing codes. Its largest line is 99285, emergency room visit (most serious) — 12% of everything it billed.
33Billing provider infoEISENHOWER MEDICAL CENTER
RANCHO MIRAGE, CA 92270
RANCHO MIRAGE, CA 92270
33aNPI1013981554assigned 02/13/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$97.77M
24GClaims2,178,373
24DCodes billed468
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#22 of 410
Median peer was paid$6.90M
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 228,478 | $8.25M | |
| 2019 | 276,979 | $10.57M | |
| 2020 | 223,539 | $9.29M | |
| 2021 | 298,388 | $13.69M | |
| 2022 | 334,303 | $15.61M | |
| 2023 | 415,059 | $20.52M | |
| 2024incomplete | 401,627 | $19.84M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 88,509 | 86,652 | $11.83M |
| A4649 | Surgical supply; miscellaneous | 5.8% | 2,948 | 2,603 | $5.71M |
| J9271 | Injection, pembrolizumab, 1 mg | 5.1% | 584 | 454 | $4.98M |
| 0450 | Emergency room services | 4.7% | 79,021 | 70,924 | $4.56M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.3% | 44,269 | 43,453 | $4.16M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.0% | 63,913 | 58,852 | $3.93M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 11,411 | 11,092 | $2.82M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.6% | 14,177 | 13,741 | $2.55M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.2% | 12,946 | 12,449 | $2.16M |
| 74178 | 2.1% | 6,217 | 6,092 | $2.08M | |
| 80053 | Comprehensive metabolic panel | 2.1% | 102,919 | 86,772 | $2.01M |
| 0510 | 1.9% | 43,082 | 35,542 | $1.82M |
456 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 25,482 | $1.76M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 50,771 | $1.75M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.7% | 69,250 | $1.68M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.6% | 108,265 | $1.60M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 115,572 | $1.58M |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | 1.6% | 20,425 | $1.52M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 22,465 | $1.21M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 25,215 | $1.19M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.2% | 6,296 | $1.13M |
| 99221 | 1.1% | 5,950 | $1.11M | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 17,710 | $1.08M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14,443 | $953K |
| 99223 | Prolong inpt eval add15 m | <1% | 8,323 | $953K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 2,062 | $938K |
| 0360 | <1% | 6,836 | $916K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,757 | $822K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 30,444 | $696K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 7,850 | $646K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 8,341 | $642K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 14,555 | $627K |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 153 | $614K |
| J0897 | Injection, denosumab, 1 mg | <1% | 629 | $613K |
| 99499 | <1% | 3,405 | $596K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 5,153 | $594K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,938 | $575K |
| 0361 | <1% | 3,039 | $555K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 71,197 | $535K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,217 | $520K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 7,749 | $516K |
| 84484 | <1% | 19,234 | $513K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 8,817 | $494K |
| 71045 | Radiologic examination, chest; single view | <1% | 25,297 | $437K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,774 | $413K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,557 | $371K |
| 83690 | <1% | 25,887 | $362K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,682 | $358K |
| 81001 | <1% | 53,011 | $357K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,651 | $351K |
| 72131 | <1% | 1,171 | $338K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 7,108 | $337K |
| 20610 | <1% | 11,461 | $335K | |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | <1% | 2,466 | $326K |
| 93971 | <1% | 2,144 | $325K | |
| 84703 | <1% | 19,747 | $319K | |
| 0710 | <1% | 5,612 | $317K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 2,848 | $291K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,015 | $291K |
| 76830 | Ultrasound, transvaginal | <1% | 2,736 | $285K |
| 97750 | <1% | 4,396 | $282K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 4,803 | $269K |
| 84702 | <1% | 10,832 | $262K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 442 | $248K |
| 73564 | <1% | 6,576 | $247K | |
| 73610 | <1% | 6,424 | $246K | |
| 73630 | <1% | 6,759 | $242K | |
| J3490 | Unclassified drugs | <1% | 51,653 | $233K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 675 | $216K |
| Z7502 | <1% | 6,582 | $211K | |
| 73110 | <1% | 5,307 | $208K | |
| 0762 | <1% | 2,433 | $201K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,743 | $200K |
| 73030 | <1% | 5,852 | $199K | |
| 87631 | <1% | 2,473 | $198K | |
| S9976 | Lodging, per diem, not otherwise classified | <1% | 3,757 | $198K |
| 83735 | <1% | 19,141 | $190K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,384 | $165K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,384 | $165K |
| 94799 | <1% | 1,920 | $161K | |
| 70486 | <1% | 525 | $158K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 4,096 | $158K |
| 99218 | <1% | 857 | $157K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,980 | $153K |
| 73130 | <1% | 3,987 | $153K | |
| 70496 | <1% | 696 | $152K | |
| 87507 | <1% | 403 | $152K | |
| 74174 | <1% | 491 | $147K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,172 | $145K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,021 | $143K |
| 87040 | <1% | 7,459 | $143K | |
| 82947 | <1% | 17,626 | $142K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,128 | $140K |
| 93976 | <1% | 422 | $139K | |
| 96367 | <1% | 3,307 | $134K | |
| 71250 | <1% | 529 | $134K | |
| 70498 | <1% | 786 | $130K | |
| 83880 | <1% | 5,198 | $128K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,026 | $128K |
| 97799 | <1% | 4,194 | $125K | |
| 83605 | <1% | 6,240 | $124K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,478 | $124K |
| 88304 | <1% | 2,320 | $120K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,958 | $119K |
| 73562 | <1% | 3,762 | $117K | |
| 76801 | <1% | 1,357 | $116K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 203 | $108K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,686 | $106K |
| C9290 | Injection, bupivacaine liposome, 1 mg | <1% | 419 | $106K |
| 0272 | <1% | 798 | $105K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,309 | $102K |
| 97763 | <1% | 2,393 | $102K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 494 | $102K |
| 86850 | <1% | 7,370 | $101K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,114 | $99K |
| 88342 | <1% | 1,219 | $97K | |
| 86923 | <1% | 806 | $96K | |
| 73502 | <1% | 2,749 | $93K | |
| 85730 | <1% | 9,723 | $92K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 1,187 | $89K |
| 97139 | <1% | 3,431 | $85K | |
| 72110 | <1% | 1,250 | $85K | |
| 94664 | <1% | 5,689 | $84K | |
| 99070 | <1% | 3,786 | $83K | |
| 85610 | <1% | 17,041 | $82K | |
| 87081 | <1% | 7,154 | $78K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,420 | $76K |
| 93308 | <1% | 561 | $74K | |
| 87186 | <1% | 4,927 | $73K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,160 | $71K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 950 | $71K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,011 | $69K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 255 | $69K |
| 71270 | <1% | 203 | $66K | |
| 72100 | <1% | 1,553 | $65K | |
| G0378 | Hospital observation service, per hour | <1% | 1,371 | $59K |
| 93970 | <1% | 224 | $58K | |
| 62323 | <1% | 739 | $57K | |
| 87641 | <1% | 1,833 | $57K | |
| 96415 | <1% | 2,063 | $57K | |
| 72128 | <1% | 230 | $57K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 31 | $56K |
| 86901 | <1% | 7,339 | $56K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 5,148 | $56K |
| 81025 | <1% | 6,278 | $56K | |
| J8501 | Aprepitant, oral, 5 mg | <1% | 1,411 | $55K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 4,774 | $54K |
| 73140 | <1% | 2,067 | $54K | |
| 86140 | <1% | 6,084 | $52K | |
| 87070 | <1% | 3,036 | $52K | |
| 96523 | <1% | 1,254 | $51K | |
| 64450 | <1% | 704 | $50K | |
| 73070 | <1% | 1,473 | $49K | |
| 97165 | <1% | 1,030 | $48K | |
| 0637 | <1% | 3,414 | $47K | |
| 87077 | <1% | 6,511 | $47K | |
| 94060 | <1% | 1,202 | $47K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,324 | $46K |
| 76870 | <1% | 434 | $46K | |
| 90715 | <1% | 1,485 | $45K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,852 | $44K |
| Q3014 | Telehealth originating site facility fee | <1% | 5,477 | $43K |
| 99217 | <1% | 687 | $43K | |
| 85379 | <1% | 1,954 | $42K | |
| 27447 | <1% | 53 | $41K | |
| 73590 | <1% | 1,213 | $40K | |
| J1437 | Injection, ferric derisomaltose, 10 mg | <1% | 27 | $40K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 688 | $40K |
| 86900 | <1% | 7,349 | $38K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,044 | $37K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,987 | $37K |
| 73080 | <1% | 909 | $37K | |
| 64483 | <1% | 991 | $36K | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,841 | $35K |
| 82550 | <1% | 2,927 | $35K | |
| 96417 | <1% | 985 | $34K | |
| 87075 | <1% | 1,960 | $33K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 565 | $32K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,010 | $32K |
| 49083 | <1% | 485 | $31K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 19,657 | $30K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 8,169 | $29K |
| 94729 | <1% | 934 | $29K | |
| 73560 | <1% | 1,087 | $29K | |
| 73090 | <1% | 834 | $29K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 18,273 | $29K |
| 99224 | <1% | 338 | $28K | |
| 84439 | <1% | 2,285 | $26K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 3,160 | $26K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 7,438 | $26K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 8,072 | $26K |
| 64493 | <1% | 576 | $25K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 18,646 | $25K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 10,655 | $25K |
| 88313 | <1% | 418 | $25K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 194 | $24K |
| 0100U | <1% | 184 | $24K | |
| 87205 | <1% | 3,232 | $23K | |
| 77002 | <1% | 625 | $23K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 23,581 | $23K |
| 84100 | <1% | 4,190 | $23K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 342 | $22K |
| 94726 | <1% | 762 | $22K | |
| 80061 | Lipid panel | <1% | 3,054 | $21K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 4,037 | $20K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 199 | $20K |
| 97162 | <1% | 1,087 | $19K | |
| 20550 | <1% | 1,348 | $19K | |
| 99454 | <1% | 1,813 | $19K | |
| C9088 | Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg | <1% | 64 | $19K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,701 | $19K |
| 81003 | <1% | 5,514 | $18K | |
| 74018 | <1% | 666 | $18K | |
| 72170 | <1% | 499 | $18K | |
| 99443 | <1% | 291 | $18K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,873 | $18K |
| 93017 | <1% | 347 | $18K | |
| 96368 | <1% | 849 | $17K | |
| 82805 | <1% | 322 | $17K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 4,122 | $17K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,544 | $17K |
| 85652 | <1% | 4,350 | $16K | |
| 70492 | <1% | 55 | $16K | |
| 88307 | <1% | 171 | $16K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 811 | $15K |
| 94760 | <1% | 3,178 | $15K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 4,441 | $15K |
| 76604 | <1% | 362 | $15K | |
| 82728 | <1% | 2,132 | $15K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 325 | $15K |
| 0250 | <1% | 534 | $15K | |
| 72040 | <1% | 361 | $15K | |
| 82607 | <1% | 2,056 | $14K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 10,966 | $14K |
| 84145 | <1% | 653 | $14K | |
| 64494 | <1% | 520 | $14K | |
| 77065 | Tomosynthesis, mammo | <1% | 214 | $13K |
| 99225 | <1% | 156 | $13K | |
| C9145 | Injection, aprepitant, (aponvie), 1 mg | <1% | 275 | $13K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,336 | $13K |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 3,121 | $13K |
| 70488 | <1% | 39 | $13K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 7,863 | $12K |
| 82746 | <1% | 1,190 | $12K | |
| 74240 | <1% | 111 | $12K | |
| 29405 | <1% | 517 | $12K | |
| 88311 | <1% | 772 | $11K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 76 | $11K |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 350 | $11K |
| 59025 | Fetal non-stress test | <1% | 467 | $11K |
| 73000 | <1% | 290 | $11K | |
| 87071 | <1% | 1,868 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,197 | $10K |
| 93880 | <1% | 136 | $10K | |
| 77066 | Tomosynthesis, mammo | <1% | 130 | $10K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,941 | $10K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 620 | $10K |
| 76642 | <1% | 163 | $10K | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 4,414 | $10K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,156 | $10K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,586 | $9K |
| 86803 | <1% | 452 | $9K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 322 | $9K |
| 74241 | <1% | 85 | $9K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 5,365 | $8K |
| J7327 | Hyaluronan or derivative, monovisc, for intra-articular injection, per dose | <1% | 12 | $8K |
| 82010 | <1% | 504 | $8K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,835 | $8K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,757 | $8K |
| 87088 | <1% | 791 | $8K | |
| 82248 | <1% | 870 | $8K | |
| 29125 | <1% | 542 | $8K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,524 | $8K |
| 96376 | <1% | 889 | $8K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,187 | $8K |
| 73700 | <1% | 26 | $7K | |
| 82375 | <1% | 331 | $7K | |
| 83550 | <1% | 1,691 | $7K | |
| 73100 | <1% | 240 | $7K | |
| 87340 | <1% | 559 | $7K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 236 | $7K |
| 51798 | <1% | 393 | $7K | |
| 97116 | <1% | 1,003 | $6K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 885 | $6K |
| 76770 | <1% | 62 | $6K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 987 | $6K |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 548 | $6K |
| 20611 | <1% | 247 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,761 | $6K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,016 | $6K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 2,507 | $5K |
| 99457 | <1% | 698 | $5K | |
| 86706 | <1% | 329 | $5K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,318 | $5K |
| C1769 | Guide wire | <1% | 64 | $5K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,827 | $5K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,033 | $5K |
| 26055 | <1% | 32 | $5K | |
| 76942 | <1% | 136 | $5K | |
| 99442 | <1% | 109 | $5K | |
| 29881 | <1% | 24 | $4K | |
| 86780 | <1% | 312 | $4K | |
| 88300 | <1% | 201 | $4K | |
| 29075 | <1% | 313 | $4K | |
| 87428 | <1% | 592 | $4K | |
| 87807 | <1% | 379 | $4K | |
| 83050 | <1% | 319 | $4K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 123 | $4K |
| 82570 | <1% | 1,074 | $4K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 3,152 | $4K |
| 29515 | <1% | 301 | $4K | |
| 64635 | <1% | 39 | $4K | |
| 87147 | <1% | 450 | $4K | |
| 90837 | Psychotherapy session, about an hour | <1% | 245 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 906 | $3K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 170 | $3K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 12 | $3K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 6,416 | $3K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,388 | $3K |
| 83615 | <1% | 954 | $3K | |
| 64488 | <1% | 59 | $3K | |
| 51701 | <1% | 47 | $3K | |
| 64636 | <1% | 54 | $3K | |
| 29827 | <1% | 12 | $3K | |
| J7318 | Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg | <1% | 12 | $3K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 4,732 | $3K |
| 88341 | <1% | 36 | $3K | |
| 88112 | <1% | 77 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 224 | $3K |
| 93296 | <1% | 264 | $3K | |
| 84132 | <1% | 61 | $3K | |
| 86704 | <1% | 155 | $3K | |
| 20526 | <1% | 240 | $3K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 284 | $3K |
| 87210 | <1% | 285 | $3K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,972 | $3K |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 492 | $2K |
| 96416 | <1% | 40 | $2K | |
| 86308 | <1% | 231 | $2K | |
| 12001 | <1% | 142 | $2K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 37 | $2K |
| 01400 | <1% | 13 | $2K | |
| 10060 | <1% | 98 | $2K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 50 | $2K |
| 86592 | <1% | 355 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 28 | $2K |
| 71101 | <1% | 24 | $2K | |
| 20605 | <1% | 50 | $2K | |
| 84550 | <1% | 372 | $2K | |
| 96521 | <1% | 92 | $2K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 80 | $2K |
| 99497 | <1% | 32 | $2K | |
| 51702 | <1% | 73 | $2K | |
| 0097U | <1% | 13 | $1K | |
| 84156 | <1% | 431 | $1K | |
| 76376 | <1% | 286 | $1K | |
| 76937 | <1% | 29 | $1K | |
| 29848 | <1% | 13 | $1K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 249 | $1K |
| 99024 | <1% | 436 | $1K | |
| 64490 | <1% | 24 | $1K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 36 | $1K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 181 | $1K |
| 99152 | <1% | 68 | $1K | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 510 | $1K |
| 62321 | <1% | 39 | $1K | |
| 73521 | <1% | 50 | $1K | |
| 83970 | <1% | 27 | $1K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,421 | $1K |
| 76882 | <1% | 38 | $1K | |
| 82272 | <1% | 395 | $980.08 | |
| 90686 | <1% | 184 | $959.26 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 416 | $883.49 |
| 97166 | <1% | 40 | $861.76 | |
| 73503 | <1% | 22 | $810.30 | |
| 99219 | <1% | 14 | $780.00 | |
| 88302 | <1% | 13 | $767.99 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 208 | $739.98 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 269 | $734.49 |
| 96402 | <1% | 55 | $730.56 | |
| 73552 | <1% | 29 | $710.80 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 117 | $710.38 |
| 87015 | <1% | 60 | $671.44 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | <1% | 41 | $655.40 |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 60 | $597.97 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 12 | $577.72 |
| 12011 | <1% | 25 | $549.21 | |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | <1% | 179 | $545.91 |
| 25600 | <1% | 27 | $537.65 | |
| 93356 | <1% | 25 | $532.68 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,195 | $521.83 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 191 | $516.37 |
| 84300 | <1% | 98 | $501.72 | |
| 80320 | <1% | 385 | $490.26 | |
| 97014 | <1% | 148 | $481.48 | |
| 86709 | <1% | 25 | $472.00 | |
| 85027 | <1% | 47 | $464.50 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 526 | $453.75 |
| 97163 | <1% | 16 | $442.69 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 76 | $399.70 |
| 29065 | <1% | 19 | $399.01 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 127 | $362.78 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 109 | $347.25 |
| 64484 | <1% | 48 | $333.20 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 29 | $306.82 |
| 87106 | <1% | 14 | $305.22 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 45 | $298.87 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 64 | $288.94 |
| 99195 | <1% | 12 | $273.39 | |
| 86880 | <1% | 36 | $257.07 | |
| 82378 | <1% | 12 | $251.40 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 54 | $231.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 30 | $225.90 |
| 99458 | <1% | 12 | $225.49 | |
| 83520 | <1% | 27 | $225.20 | |
| 84403 | <1% | 29 | $205.59 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 45 | $205.54 |
| 84165 | <1% | 25 | $193.55 | |
| 97161 | <1% | 13 | $189.36 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 107 | $171.15 |
| 89051 | <1% | 15 | $152.80 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 232 | $151.68 |
| 82784 | <1% | 32 | $138.55 | |
| 82043 | <1% | 164 | $128.56 | |
| 0003A | <1% | 12 | $120.00 | |
| 96401 | <1% | 30 | $119.38 | |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | <1% | 14 | $118.82 |
| 29085 | <1% | 14 | $117.60 | |
| 0451 | <1% | 801 | $114.85 | |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 26 | $113.40 |
| 84153 | <1% | 12 | $112.72 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 130 | $100.15 |
| 20552 | <1% | 12 | $98.69 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 132 | $91.96 |
| 64615 | <1% | 13 | $91.01 | |
| 64491 | <1% | 12 | $88.20 | |
| G0008 | Administration of influenza virus vaccine | <1% | 311 | $77.55 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 54 | $71.28 |
| J0290 | Injection, ampicillin sodium, 500 mg | <1% | 41 | $51.31 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 23 | $43.70 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 37 | $34.10 |
| 90653 | <1% | 28 | $33.57 | |
| 99453 | <1% | 26 | $24.88 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 50 | $24.45 |
| 85045 | <1% | 12 | $19.72 | |
| 86359 | <1% | 12 | $19.57 | |
| 86360 | <1% | 12 | $17.77 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 17 | $17.00 |
| 87185 | <1% | 14 | $13.16 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 25 | $6.78 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 27 | $3.30 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 102 | $0.01 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 86 | $0.01 |
| 91300 | 0% | 66 | $0.00 | |
| 0002A | 0% | 30 | $0.00 | |
| 1160F | 0% | 13 | $0.00 | |
| G9744 | Patient not eligible due to active diagnosis of hypertension | 0% | 14 | $0.00 |
| 3288F | 0% | 13 | $0.00 | |
| 94761 | 0% | 12 | $0.00 | |
| 90694 | 0% | 92 | $0.00 | |
| 3008F | 0% | 13 | $0.00 | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | 0% | 62 | $0.00 |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| 0001A | 0% | 28 | $0.00 | |
| 1170F | 0% | 13 | $0.00 | |
| 80329 | 0% | 100 | $0.00 | |
| 0270 | 0% | 17 | $0.00 | |
| Q4051 | Splint supplies, miscellaneous (includes thermoplastics, strapping, fasteners, padding and other supplies) | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMASSIELLO, MARTIN (PRESIDENT AND CEO)
| Provider | Location | Paid |
|---|---|---|
| Eisenhower Medical Center | La Quinta, CA | $6K |
| Eisenhower Medical Center | Rancho Mirage, CA | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.